C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV

Key Who May Qualify: - Use of adequate contraception for females of childbearing potential - Must be direct-acting antiviral (DAA)-treatment-naïve (never exposed to an approved or experimental DAA for HCV) - Documented medical history compatible with chronic HCV - Either no liver cirrhosis or with compensated liver cirrhosis - If HIV-1-positive, must meet the following 2 criteria: 1. Antiretroviral (ARV) regimen for \>8 weeks prior to screening visit, with CD4 T-cell count \>200 cells/mm3 and plasma HIV-1 RNA \<LLOQ 2. Suitable ARV treatment and not taking any contraindicated medications Key Who Should NOT Join This Trial: - Pregnant or breastfeeding - Co-infected with hepatitis B virus - Abuse of alcohol and/or illicit drug use that could interfere with adherence to study requirements as judged by the investigator - Prior exposure to any HCV DAA - Requirement of any prohibited medications - Use of other investigational drugs within 30 days of dosing - History or signs of decompensated liver disease (decompensated cirrhosis) - History of hepatocellular carcinoma (HCC) - Any other clinically significant medical condition that, in the opinion of the investigator, would jeopardize the safety of the subject or impact the validity of the study results Always talk to your doctor about whether this trial is right for you.